Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

20 Dec 2018

• By Sten Stovall

Puma's CEO voiced confidence the biotech's lead asset Nerlynx will be approved in third-line HER2-positive metastatic breast cancer after its Phase III NALA study met co-primary endpoints.

Carcinoma — Filings to be based on Positive top line results from Phase III NALA trial • Source: Shutterstock

Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

More from Anticancer

More from Therapy Areas